Try our beta test site
5 studies found for:    AT7519
Show Display Options
Rank Status Study
1 Completed Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: AT7519M;   Drug: Bortezomib
2 Recruiting Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Metastatic Malignant Solid Neoplasm;   Unresectable Solid Neoplasm
Interventions: Drug: CDKI AT7519;   Other: Laboratory Biomarker Analysis;   Drug: Onalespib;   Other: Pharmacological Study
3 Completed AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma
Conditions: Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: CDKI AT7519;   Other: laboratory biomarker analysis
4 Completed A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: AT7519M
5 Completed A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: AT7519M

Study has passed its completion date and status has not been verified in more than two years.